NCT07085429

Development of Clinical and Biological Database on Bronchial Cancer

Development of a Prospective Monocentric Clinico-Biological Database for Bronchial Cancer

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 750 (estimated)
• Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to bronchial cancer.

Detailed description

Lung cancer is the leading cause of cancer-related mortality and the third most commonly diagnosed cancer. In France in 2018, it accounted for 46,363 new cases and 33,117 deaths. The overall 5-year survival rate across all stages and sexes is 20%. Diagnosis is most often made at the metastatic stage, which significantly worsens the prognosis. Since 2020, the standard treatment for such cases has been the administration of intravenous chemo-immunotherapy, in the absence of a molecular alteration that allows for access to an oral targeted therapy. Immunotherapy and targeted therapies have considerably improved the prognosis for some patients, but the vast majority experience therapeutic resistance, either early or delayed. The prognostic and predictive mechanisms of treatment response are poorly understood and vary greatly between histological and molecular subtypes. It is therefore crucial to gain a better understanding of these mechanisms in order to ultimately identify new therapeutic avenues to improve patient outcomes. The first step in this process is to establish a tissue and blood biobank from patients with bronchial carcinoma (both small-cell and non-small-cell) treated at our center. The Clinical Biological DataBase (BCB) is a tool: * for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials; * to help scientists understand and explain phenomena ranging from the interaction of molecules to the whole metabolism of the organism in normal and pathological situations; * to identify potential strategies for prevention, diagnosis, management and analysis of cancer subtypes.

Conditions

• Lung Cancer
• Bronchial Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Blood and tissue sampling	Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. During the blood samples taken for diagnosis and / or treatment when possible. Additional samples for research purposes will be carried out, these blood samples will be collected: * before any therapeutic intervention (T1) for a total volume of 36mL, * prior to surgery (T-Surg) for a total volume of 24mL, * at each progression (T2a, b, c…) for a total volume of 24mL, * at the end of follow-up (T3) for a total volume of 24mL.

Timeline

• Start date: 2025-09-01
• Primary completion: 2030-09-01
• Completion: 2040-09-01
• First posted: 2025-07-25
• Last updated: 2025-07-25

Locations

1 site across 1 country: France